Profiling circulating DNA and RNA to identify mechanisms of therapeutic resistance and response in metastatic castration-resistant prostate cancer

分析循环 DNA 和 RNA，以确定转移性去势抵抗性前列腺癌的治疗抵抗和反应机制

• 批准号: nhmrc : 1098647
• 负责人: A/Pr Arun Azad
• 金额: $ 33.18万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/profiling-circulating-dna-prostate-cancer/662390
• 关键词: Profiling; circulating; DNA; RNA; identify

Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.

Enzalutamide是一种强效激素治疗药物，可提高晚期前列腺癌男性患者的生存率。不幸的是，所有前列腺癌最终都会对Enzalutamide产生耐药性，并且并非所有男性最初都对治疗有反应。我将寻找预测哪些男性从enzalutamide治疗中获益的血液标志物，并试图了解enzalutamide耐药是如何发生的。这可能导致Enzalutamide的更有效使用，从而在晚期前列腺癌中获得更好的结局。